Topotecan for lung cancer
Newly diagnosed stage IIIlIV ovarian cancer patients. Proc Soc Clin Oncol 12: 814a, 1993 Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943, 1993 Rowinsky ED, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010, 1993 Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, TzyJyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K, Toomasi F, Kelsen D: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensificationusing recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 85: 1499, 1993 Crawford J, O'Rourke MA: Vinorelbine Navelbine ; carboplatin combination therapy: Dose intensification with granulocyte colony-stimulating factor. Semin Oncol 21: 73, 1994 Peters WP, Rosner G, Vredenburg J, Meisenberg B, Gilbert C, Kurtzberg J: Comparative effects of granulocyte macrophage colony stimulating factor GM-CSF ; and granulocyte-colony stimulating factor G-CSF ; on priming peripheral blood progenitor cells for usewith autologous bonemarrow after high-dose Chemotherapy. Blood 81: 1709, 1993 Bensinger W1, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J, Chauncey T, Storb R, Buckner CD: Peripheral blood stem cells PBSCs ; collected after recombinant granulocyte colony stimulating factor rhGCSF ; : An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87: 825, 1994 Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR. Snyder DS, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, Margolin KA, Woo D, Niland JC, Forman SJ: High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colonystimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 12: 2176, 1994 Faucher C, le Corroller AG, Blaise D, Novakovitch G, Manonni P, Moatti JP, Maraninchi D: Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: Clinical assessment and cost-effectiveness. Bone Marrow Transplant 14: 895, 1994 Row15 1. Weaver CH, Buckner CD, Longin K, Appelbaum ley S, Lilleby K, Miser J, Storb R, Hansen JA, Bensinger W: Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 82: 1981, 1993 Bensinger WI, Weaver CH, Appelbaum FR. Rowley S, Demirer T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85: 1655, 1995 Sheridan WP: Cytokine-only approaches to mobilization of progenitor cells, in Morstyn G, Sheridan WP eds ; : Cell Therapy. Cambridge, UK, Cambridge University, 1996, p 146 154. Mueller BU, Jacobsen F, Butler KM, Husson RN, Lewis LL, Pizzo PA: Combination treatment as azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. J Pediatr 121: 797, 1992 Miles SA, Mitsuyasu RT, Lee K, Moreno J, Alton K, Egrie.
Topotecan order
Process Development Team, Semiconductor R&D Center, Samsung Electronics Co. Ltd. Contact e-mail: sunwoo jsj.lee samsung Carbon nanotube CNT ; has been considered as a good electrical conductor, because of its unique shape with one dimensional graphene tubular structure, ballistic transport property and strong stability. These properties enable CNT to be a promising candidate for vertical interconnection material in a nano-scale feature competing with copper for the future memory devices. In this work, vertical interconnection using multi-wall carbon nanotubes MWCNTs ; is implemented into the full 6-inch Si wafer for semiconductor device integration. Integration processes are implemented by following sequential steps of conventional semiconductor processes; 1 ; Formation of bottom electrode lines covered with ultra thin CNT catalyst layer having sub 5 nm thickness 2 ; Patterning 240 nm diameter via hole using conventional dry etch process 3 ; CNTs are grown on the exposed catalyst surface at the bottom of the via hole by decomposing methane gas at 600 deg. C. using remote type microwave-PECVD system. 4 ; Planarizing over-grown CNTs using chemical mechanical polishing using capping layer 5 ; Ohmic contact layer and top metal lines formation. The via resistance is measured at a single contact of CNT via. The via resistance of several hundred Ohm with CNT density of 51010 cm2 is obtained with small resistance variation within a wafer, which corresponds to 10 kOhm per one MWCNT of the diameter of 10 nm. This result demonstrates that CNT via-module can be implemented into the conventional manufacturing process with compatibility. However research to improve the electrical properties should be investigated intensively.
Monoxide-induced relaxation in the guinea pig ileal smooth muscle. J Vet Med Sci 63: 389-393, 2001. Kwon SC, Ozaki H, and Karaki H. NO donor sodium nitroprusside inhibits.
Subcortical system. area Thus, of the central it has important nervous antihis.
Physical activity was defined as the average time the subject sat still while receiving placebo. The low, intermediate, and high doses of methylphenidate were 0.5, 0.8, and 1.5 mg kg per day in two divided doses. b Hyperactive boys spent an average of 20% less time sitting still than the most active healthy comparison subject. c For both axes, the center of the ellipse indicates the mean, and the half-width indicates the standard deviation. d Nonmedicated; values on the vertical axis are arbitrary. e Nonsignificant group effect F 0.63, df 1, 8, p 0.63 ; . f Significant group effect F 6.75, df 1, 8, p 0.04 ; . g Significant group effect F 15.98, df 1, 8, p 0.004.
Topotecan for lung cancer
Stolic parameters, i.e. deceleration rate and early vs. late LV filling velocities ratio data not shown ; . Heart rate did not differ between the groups. MAP was lower in the GH group vs. that in the NaCl group, but was not significantly changed by Hex treatment, although there was a tendency toward lower MAP in the Hex100 group. End-systolic wall stress was increased in all NaCl rats vs. intact rats, but there were no significant effects of treatment. There were no effects on LV geometry variables such as ESA and EDA and toradol.
Cost of Topotecan
Topotecan was administered at 1.5 mg m2 or 1.2 mg m2 in patients with prior pelvic radiation therapy ; intravenously on days 1 to 5 every 3 weeks. Patients receiving the lower dose could be escalated to 1.5 mg m2 after cycle 1 if they had no toxicities greater than grade 1. Doses were calculated from actual body weight. For each cycle, doses were adjusted according to the prior platelet and absolute neutrophil count nadirs. Doses were adjusted for hepatic function, gastrointestinal toxicities, or other grade 3 4 toxicities. Toxicities were assessed using the National Cancer Institute common toxicity criteria.7 Outcome was assessed using standard ECOG response criteria.8 Survival was measured from the first day of treatment.
Neutropenic sepsis. Greater myelosuppression is also likely to be seen when HYCAMTIN is used in combination with other cytotoxic agents, thereby necessitating a dose reduction. However, when combining HYCAMTIN with platinum agents e.g., cisplatin or carboplatin ; , a distinct sequence-dependent interaction on myelosuppression has been reported. Coadministration of a platinum agent on day 1 of HYCAMTIN dosing required lower doses of each agent compared to coadministration on day 5 of the HYCAMTIN dosing schedule. For information on the pharmacokinetics, efficacy, safety, and dosing of HYCAMTIN at a dose of 0.75 mg m2 day on days 1, 2, and 3 in combination with cisplatin 50 mg m2 on day 1 for cervical cancer, see CLINICAL PHARMACOLOGY, CLINICAL STUDIES, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION. Pregnancy: Pregnancy Category D. See WARNINGS. ; Nursing Mothers: HYCAMTIN is contraindicated during breastfeeding see CONTRAINDICATIONS ; . Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Of the 879 patients with metastatic ovarian cancer or small cell lung cancer in clinical studies of HYCAMTIN, 32% n 281 ; were 65 years of age and older, while 3.8% n 33 ; were 75 years of age and older. Of the 140 patients with stage IV-B, relapsed, or refractory cervical cancer in clinical studies of HYCAMTIN who received HYCAMTIN plus cisplatin in the randomized clinical trial, 6% n 9 ; were 65 years of age and older, while 3% n 4 ; were 75 years of age and older. No overall differences in effectiveness or safety were observed between these patients and younger adult patients, and other reported clinical experience has not identified differences in responses between the elderly and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out. There were no apparent differences in the pharmacokinetics of topotecan in elderly patients, once the age-related decrease in renal function was considered see CLINICAL PHARMACOLOGY ; . This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function see DOSAGE AND ADMINISTRATION ; . ADVERSE REACTIONS Ovarian Cancer and Small Cell Lung Cancer: Data in the following section are based on the combined experience of 453 patients with metastatic ovarian carcinoma, and 426 patients with small cell lung cancer treated with HYCAMTIN. Table 4 lists the principal hematologic toxicities, and Table 5 lists non-hematologic toxicities occurring in at least 15% of patients and toremifene.
Topotecan target
| Weekly topotecan and ovarian cancerFormulas 1. Logistics-Based Estimates: Estimated use for Next Quarter Number of Units Dispensed in past `n' quarters `n' Where `n' is number of quarters consumed or distributed to clients or consumers 2. Service Data Estimates: A. Estimated Use of Method for Next Period Estimated Total Visits for this Method X Number of Units Dispensed at Each Visit OR B. Estimated Use of Method for Next Period Estimated Current Users for this Method X Number of Units required serving a Current User 3. Population-Based Estimates: i. Number of users No. of MWRA X proportion of use target ; ii. Number of users for each method No. of users X proportion use by a given method iii. Annual usage of a given method No. of users a given method X No. of units per year.
Table 1. Average density values for both parasympathetic ChAT ; and sympathetic TH ; innervation from different intercaval regions n 3 and torsemide.
June 15, 200 long hj, bundy bn, grendys ec et al randomized phase iii trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study.
|
43 Hald T, Agrawal O and Kantrowitz A, "Studies in stimulation of the bladder and its motor nerves" Surgery 1966 ; , 60: pp. 848856. 44. Nashold B S, Friedman H and Boyarski S, "Electrical activation of micturation by spinal cord stimulation", J. Surg. Res. 1971 ; , 11: pp. 144147. 45. Jonas U, Heine J P and Tanagho E A, "Studies on the feasibility of urinary bladder evacuation by direct spinal cord stimulation I. Parameters of most effective stimulation", Invest. Urol. 1975 ; , 13: pp. 151153. 46. Jonas U, James L W and Tanagho E A, "Spinal cord stimulation versus detrusor stimulation: a comparative study in six acute dogs", Invest. Urol. 1975 ; , 13: pp. 171174. 47. Thurhoff J W, Bazeed M A and Schmidt R A, et al. "Regional topography of spinal cord neurons innervating the pelvic floor and bladder neck in the dog: a study by combined horseradish peroxidase histochemistry and autoradiography", Urol. Int. 1982 ; , 37: pp. 110120. 48. Tanagho E A, Schmidt R A, "Bladder pacemaker: scientific basis and clinical future", Urol. 1982 ; : 20; pp. 614619. 49. Schmidt R A, Bruschini H and Tanagho E A, "Sacral root stimulation in in controlled micturation: peripheral somatic neurotomy and stimulated voiding", Invest. Urol. 1979 ; : 17: pp. 130134. 50. Schmidt R A, Jonas U and Oleson K A, et al. "Sacral nerve stimulation for treatment of refractory urinary urge incontinence", J. Urol. 1999 ; , 162: p. 352. 51. Abrams P, Blaivas J G and Fowler C H, et al. "The role of neuromodulation in the management of urinary urge incontinence", BJU Int. 2004 ; , 91: pp. 355359. 52. Ibid. 53. Siegel S W, Catanzaro F and Dijkema H E, et al. "Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency frequency and retention", Urol. 2000 ; , 56 Suppl 1 ; : pp. 8791. 54. Hassouna M M, Siegel S W and Nyeholt A A et al, "Sacral modulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety", J. Urol. 2000 ; , 163 6 ; : pp. 1, 8491, 854. Jonas U, Fowler C J and Chancellor M B, et al., "Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation", J. Urol. 2001 ; , 165 1 ; : pp. 1519. 56. Janknegt R A, Hassouna M M and Siegel S W et al., "Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence", Eur. Urol. 2001 ; , 39 1 ; : pp. 101106. 57. Ibid. 58. Harrison N W, "Stress incontinence and the use of implanted electronic stimulators in children", Proc. Roy. Soc. Med. 1971 ; , 64: p. 128. 59. Stoller M L, Copeland S, Millard A R J and Murnaghann G F, "The efficacy of acupuncture in reversing unstable bladder in pig-tailed monkeys", J. Urol. 1987 ; , 104A. 60. McGuire E L, Ziang S C, Horwinski E R and Lytton B, "Treatment of motor and sensory detrusor instability by electrical stimulation", J. Urol. 1983 ; : 129: pp. 7879. 61. Stoller M S, "Afferent nerve stimulation for pelvic floor dysfunction", Eur. Urol. 1999 ; , 35 Suppl 16 ; : A 62. Ibid. See article for specific results. ; 63. Van der Pal F, van Balken M R, Heesakkers J P F A, Debruyne F M J and Bemelmans B L H, "Maintenance treatment in successfully PTNS treated patients with refractory overactive bladder syndrome is a necessity", Department of Urology, Nijmegan University Hospital, Arnhem, The Netherlands. Unpublished Abstract. 64. Congregado Ruiz B, Pena O M, Martinex P C, Duenas E L and Lopez A L, "Peripheral Afferent Nerve Stimulation for Treatment of Lower Urinary Tract Irritative Symptoms", European Urology 2004 ; , 45: pp. 6569. 65. Vandoninck V, van Balken M R, Agr E F, Petta F, Caltagirone C, Heesakkers J P F A, Kiemeney L A L M, Debruyne F M J and Bemelmans B L H, "Posterior Tibial Nerve Stimulation in the Treatment of Urge Incontinence", Neurourology and Urodynamics 2003 ; , 22: pp. 1723. 66. Vandoninck V, van Balken M R, Agr E F, Petta F, Micali F, Heesakkers J P F A, Debruyne F M J, Kiemeney L A L and Bemelmans B L H, "Percutaneous Tibial Nerve Stimulation in the Treatment of Overactive Bladder: Urodynamic Data", Neurourology and Urodynamics 2003 ; , 22: pp. 227232. 67. Knipscheer B, Van der Pal F, Bade J and Boon T, "Percutaneous Tibial Nerve Stimulation PTNS ; for the Treatment of Interstitial Cystitis IC ; , A Prospective Multicenter Study", J. Urology 2002 ; , 167 4S ; : p. 67. 68. Govier F E, Litwiller S, Nitti V, Kreder K J Jr and Rosenblatt P, "Percutaneous Afferent Neuromodulation for the Refractory Overactive Bladder: Results of a Multicenter Study", J. Urology 2001 ; , 165: pp. 1, 1931, 198. van Balken M R, Vandoninck V, Gisolf K W H, Vergunst H, Keimeney L A L M, Debruyne F M J and Bemelmans B L H, "Posterior Tibial Nerve Stimulation as Neuromodulative Treatment of Lower Urinary Tract Dysfunction", J. Urology 2001 ; , 166: pp. 914918. 70. Klingler H C, Pycha A, Schmidbauer J and Marberger M, "Use of Peripheral Neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study", Urology 2000 ; , 56: pp. 766771. 71. De Gennaro M, Capitanucci M L, Mastracci P, Silveri M, Gatti C and Mosiello C, "Percutaneous Tibial Nerve Neuromodulation Is Well Tolerated in Children and Effective for Treating Refractory Vesical Dysfunction" J. Urology 2004 ; , 171: pp. 1, 9111, 913 and tracleer.
Topotecan dabur
To standard chemotherapies, including platinum drugs, taxanes, gemcitabine, topotecan and doxorubicin.
Received placebo mean 24 h dose 35 SD 20.4 ; mg vs 32.7 27.4 ; mg vs 54.9 28.3 ; mg, respectively; P 0.05 ; . Mean morphine sparing during PCA for paracetamol and diclofenac was 36% and 40%, respectively. Figure 1 shows cumulative PCA morphine consumption. Patients who received paracetamol and diclofenac used less morphine than those who received placebo, from 2 h after starting PCA. There were no significant differences in pain or sedation scores at 8 and 16 h, or global 24 h scores for worst pain, average pain relief and average nausea. Global 24 h average pain scores were significantly different overall P 0.015 ; and lower in patients who received diclofenac compared with the other groups P 0.008 vs paracetamol; P 0.08 vs placebo and trandolapril.
1. Kufrin D, Eslin DE, Bdeir K, et al. Antithrombotic thrombocytes: ectopic expression of urokinasetype plasminogen activator in platelets. Blood. 2003; 102: 926-933. Yarovoi H, Kufrin D, Eslin DE, et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood. 2003; 102: 40064013. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol. 1989; 9: 1233-1242. Miyazaki K, Reisine T, Kebabian JW. Adenosine 3', 5'-monophosphate cAMP ; -dependent protein kinase activity in rodent pituitary tissue: possible role in cAMP-dependent hormone secretion. Endocrinology. 1984; 115: 1933-1945. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998; 101: 613-624. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998; 95: 9524-9529. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet. 1995; 10: 119-1121. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999; 5: 5663. Eslin DE, Zhang C, Samuels KJ, et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood. 2004; 104: 3173-3180. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood. 1994; 83: 351-356. Wilcox DA, Shi Q, Nurden P, et al. Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. J Thromb Haemost. 2003; 1: 2477-2489. Nurden P, Poujol C, Durrieu-Jais C, et al. Labeling of the internal pool of GPIIb-IIIa in platelets by c7E3 Fab fragments abciximab ; : flow and endocytic mechanisms contribute to the transport. Blood. 1999; 93: 1622-1333. Kaplan KL, Broekman MJ, Chernoff A, Lesznik GR, Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood. 1979; 53: 604-618. Lamont PA, Ragni MV. Intracellular co-localization of Factor VIII and von Willebrand Factor is necessary for in vivo FVIII secretion [abstract]. Blood. 2004; 104; 15a. Abstract 41. 15. Xu L, Nichols TC, McCorquodale S, Dillow A, Merricks E, Ponder KP. DDAVP-induced increase of factor VIII activity in blood is likely due to release of factor VIII that is synthesized by endothelial cells [abstract]. Blood. 2004; 104; 199a. Abstract 692. 16. Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA. 1997; 94: 11851-11856. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest. 2004; 113: 1025-1031.
Topotecan stability
USA ; in women with relapsed ovarian cancer was demonstrated in studies comparing single-agent PLD with paclitaxel [4] or topotecan [5, 6]. PLD was associated with a lower risk of musculoskeletal disorders and alopecia versus paclitaxel [4] and fewer grade 3 4 toxicities versus topotecan [5, 6]. Unlike experience with conventional doxorubicin, patients treated with PLD report handfoot syndrome HFS ; and stomatitis [4, 5]. However, the efficacy and tolerability profile of single-agent PLD in advanced ovarian cancer support evaluation of a PLDcarboplatin doublet in this setting and tranylcypromine.
14.2. HOW THE PRODUCT INFLUENCES PROCESS DECISIONS Genetically engineered cells can be used to make two major classes of products: proteins and nonproteins. Nonprotein products can be made by metabolically engineering cells, inserting DNA-encoding enzymes that generate new pathways or pathways with an and topotecan.
Orthopaedic Surgery, Earl V. Fogelberg, Eric and Fransk E. Stinschfield Dislocation, Radial. Report of a John C. Shaw amid Framuk C and treprostinil.
In type 1 diabetes, your body doesn't make enough insulin. In type 2 diabetes, your cells cannot use the insulin your body makes. In both types of diabetes, sugar builds up in your bloodstream because it cannot enter the cells. Without sugar for fuel in the cells, your body lacks energy. Sugar stays in your blood and you have high blood sugar levels. High blood sugar levels can damage your blood vessels, and over a long period of time can result in serious problems.
Also reported that subtoxic concentrations of topotecan potentiated irradiation-induced killing and exponential growth of chinese hamster ovary and p388 murine leukemia cell lines and triac.
Topotecan dna
The role of the united states pharmacopeia pharmacist, high bone mass syndrome, lamisil jamur, whooping cough pathophysiology and vertebroplasty omaha. Clomid days 1-5, thymosin feedback, ventral of foot and informed consent software or xeric landscaping ideas.
Topotecan japan
Topotecsn, topofecan, topottecan, yopotecan, topitecan, t9potecan, otpotecan, topotwcan, 5opotecan, toopotecan, opotecan, topoteacn, topoyecan, ttopotecan, topotcean, fopotecan, topoteccan, toptecan, topotecam, topotevan.
Topotecan and ovarian cancer
Topotecan order, topotecan for lung cancer, cost of topotecan, topotecan target and weekly topotecan and ovarian cancer. Topotecan dabur, topotecan stability, topotecan dna and topotecan japan or topotecan and ovarian cancer.
|
